BioIVT is now a Promega Service Provider offering a range of Promega bioassays to support immunology and immune-oncology research in addition to developing specific assays with client-provided cells and reagents. Our PHASEZERO® Research Services Team has extended their services capabilities to support scientists in screening novel therapeutics by offering a range of robust Promega Bioassays, including measurement of ADCC for out of the box actionable data as well as ability to develop specific data with client-provided target cells.
With data that corresponds to classic ADCC assays, Promega ADCC Reporter bioassays reduce variability while providing consistent reproducibility. BioIVT’s PHASEZERO® Research Team, with over 20 years of expertise in human-based cell and molecular research, continues to expand our support of immuno-oncology drug development and validation with these surrogate reporter bioassay capabilities. These assays allow the measurement of the following:
- measure potency of monoclonal antibody (mAb) biological drug
- measure Fc effector function
- measure potency of unknown biologic to a reference standard
- measure stability (loss of activity due to heat stress)
For more information about our Promega Service Provider Capabilities, please click here (Link to Promega technical page).